Trasis and Beijing PET Technology strengthen long-term partnership with new joint venture to support nuclear medicine in China

Ans, Belgium, 25 november 2025, Trasis SA and Beijing PET Technology Co. Ltd. announce the creation of a joint venture in China to further structure and expand their more than ten-year collaboration in the field of nuclear medicine. The new entity will combine Trasis’s expertise in radiopharmaceutical technologies with Beijing PET Technology’s experience in the Chinese healthcare market and established distribution network. Trasis holds a majority stake in the joint venture.

Jessie Yu, CEO of Beijing PET Technology, explained: “China is significantly expanding its nuclear medicine sector through government planning and investment, aiming to triple or even quadruple its size by 2035. The policies such as the “Mid-and Long-Term Development Plan for Medical Isotopes” and “Healthy China 2030” aim to increase patient services to over 10 million annually. We are convinced that the new joint venture with Trasis and its market leading technologies is a key driver in achieving this ambition and improving healthcare for the Chinese population”.

Gauthier Philippart, CEO of Trasis, stated: “We are happy to ensure a structured continuation of our long-standing collaboration with Beijing PET Technology. We share the same values of proximity with our users, and we want to be at the forefront of innovation in nuclear medicine. By combining local presence with our radiopharmaceutical expertise, we intend to provide the Chinese market with reliable, high performance and high-quality solutions within a clear and stable framework.”

Xiaoping Hu, CTO of Beijing PET Technology, commented: “Beijing PET Technology and Trasis have been working together for over a decade. The joint venture formalizes this collaboration and provides a solid platform for further development in China, while ensuring the continuity of our services for our existing customers and partners. We are delighted to deepen a partnership built on trust, shared values and a common ambition to support nuclear medicine.”

Emmanuel Bertrand, Business Developer of Trasis, said: “Our joint venture is designed to improve access to advanced nuclear medicine solutions for healthcare providers and patients in China. It is also rooted in the shared values of both companies: proximity to users through service, technical excellence, and a strong sense of team and collaboration. It will develop our joint presence and added value services to respond more efficiently to the needs of hospitals, research centers and radiopharmaceuticals manufacturing sites in China.”

Jean-Luc Morelle, CTO of Trasis, added: “This is a great opportunity for Trasis to get closer to Chinese customers and patients as well as to progress and innovate for the benefit of our customers worldwide. By working even more closely with Beijing PET Technology, we can translate our shared commitment to excellence and service into concrete solutions that can be deployed in the field.”

The joint venture will operate under the brand Trasis Beijing. As the deal closing is planned early 2026, the assets and business activities will be progressively transferred from current operating company “Beijing PET Technology Co. Ltd.” to the new legal entity, in line with the applicable legal and contractual framework.

Trasis has been advised by VVR International and Leaf Legal. Beijing PET Technology has been advised by Fangda Partners.

About Trasis

Founded in 2004, the Trasis group has grown into a global leader in nuclear medicine, specializing in the design and manufacture of advanced equipment and solutions for the diagnosis and treatment of cancer and neurodegenerative diseases. Every year, nearly 20 million new cancer cases are diagnosed worldwide, and over 4 million patients benefit from Trasis’ innovative, automated medical technologies that improve care quality while minimizing side effects. Operating in over 60 countries across hospital nuclear medicine departments, research centers, and radiopharmaceutical companies, Trasis provides integrated solutions spanning the development, production, and administration of radiotracers. Between 2019 and 2024, Trasis achieved an average annual growth rate of 33%, far outpacing the sector’s 10% growth, and reached €72 million in sales in 2024. With approximately 430 employees located in Belgium, France, the United States, China, and beyond, more than 99% of its production is exported globally. Trasis also supports the biotech and medtech ecosystem by investing in and mentoring local start-ups, contributing to a future where nuclear medicine transforms therapeutic pathways for patients worldwide.

Learn more at www.trasis.com.

About Beijing PET Technology

Founded in 2001 and headquartered in Beijing, China, Beijing PET Technology Co., Ltd. is a national high-tech enterprise specializing in the field of nuclear medicine. With 30 skilled staff, the company is dedicated to the distribution of radiopharmaceutical synthesis equipment and R&D and production of consumables. As the exclusive distributor in China for Belgium’s TRASIS synthesizers since 2014, it has established a leading market presence in the sector. With multiple patents and award-winning innovations, Beijing PET collaborates closely with medical institutions to advance clinical applications and scientific research in nuclear medicine. Committed to supporting precision medicine, the company provides reliable technological solutions and continues to contribute to the high-quality development of China’s nuclear medicine industry.

Media contacts

Trasis SA: communication@trasis.com
Laurie Brion, Communication Manager
Jacques Galloy, Board member

Beijing PET Technology
Jessie Yu , CEO
Xiaoping Hu, CTO

Trasis opens a new chapter in China

Related contents

Trasis: Finalist for Entrepreneur of the Year®

2024: a record-breaking year for Trasis